Iga Nephropathy
📧 Sign up to get email alerts when something new happens for Iga Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN [Phase 2]
This clinical trial update indicates that a Phase II study of HSK39297 tablet for primary IgA nephropathy is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Atrasentan in Patients With IgA Nephropathy [Phase 3]
Phase 3 clinical trial update for atrasentan in IgA nephropathy; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy [Phase 2]
A Phase 2 clinical study evaluating CM338 for IgA nephropathy is currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-10Clinical Trial Update: A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy [Phase 2]
A Phase 2 clinical trial update evaluating the efficacy and safety of HS-10390 for primary IgA nephropathy; the study is currently not yet r…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects [Phase 1]
First-in-human Phase 1 trial to evaluate safety, tolerability, and pharmacology of HS-10390 in healthy subjects; the study lists IgA nephrop…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-09-25Clinical Trial Update: Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD [Phase 2, Phase 3]
Clinical trial update describes a Chinese medicine Yi-Qi-Qing-Jie Herbal Compound combined with immunosuppressants being studied in IgA neph…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy [Phase 2]
A Phase 2 study of RC18 administered subcutaneously to subjects with primary IgA nephropathy has been completed.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN
This update reports the completion of a replication trial evaluating TRF-budesonide for IgA nephropathy. The results are not provided in the…
-
FDA label_change · 2024-09-05FDA Approved: FILSPARI — Supplemental Application (Travere Therapeutics, Inc.)
FDA approved a supplemental application for FILSPARI (sparsentan) submitted by Travere Therapeutics, Inc., relating to changes or expansion …
-
CLINICAL_TRIALS research · 2024-08-30Clinical Trial Update: Effect of Finerenone in IgA Nephropathy [Phase 3]
Phase 3 clinical trial evaluating finerenone for IgA nephropathy is listed as not yet recruiting, with Zhejiang University as sponsor.
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy [Phase 4]
Phase 4 clinical trial is evaluating the efficacy and safety of a combination of probiotics with enteric-coated budesonide capsules in patie…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy [Phase 3]
Phase 3 study evaluating sparsentan for IgA nephropathy has posted results in July 2024; the trial is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
This document reports the completion of a clinical trial evaluating the efficacy and safety of finerenone for treating IgA nephropathy.
-
FDA approval · 2024-06-05FDA Approved: TARPEYO — Supplemental Application (Calliditas Therapeutics AB)
FDA approved a supplemental application for Tarpeyo (budesonide) submitted by Calliditas Therapeutics AB.
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: The Effect of OSA on Severity and Prognosis of Patients With IgAN
A protocol to study how obstructive sleep apnea affects the severity and prognosis of IgA nephropathy; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2024-05-28Clinical Trial Update: The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
This entry reports the ongoing status of the Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA), sponsored by Ruijin Hospital,…
-
CLINICAL_TRIALS research · 2024-05-06Clinical Trial Update: Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD [Phase 3]
A Phase 3 clinical trial evaluating the efficacy of immunosuppressive therapy for IgA nephropathy in patients with stage 3 or 4 chronic kidn…
-
FDA approval · 2023-12-20FDA Approved: TARPEYO — Supplemental Application (Calliditas Therapeutics AB)
FDA approved a supplemental application for Tarpeyo (budesonide) submitted by Calliditas Therapeutics AB.
-
CLINICAL_TRIALS trial_result · 2023-12-08Clinical Trial Update: A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) [Phase 2]
The Phase 2 trial of cemdisiran in adults with immunoglobulin A nephropathy (IgAN) has been terminated; results have been posted.
-
FDA approval · 2023-10-18FDA Approved: FILSPARI — Supplemental Application (Travere Therapeutics, Inc.)
The FDA has a supplemental application (AP) for Filspari (sparsentan) from Travere Therapeutics, Inc., currently under regulatory review. Th…
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy [Phase 4]
A randomized, controlled Phase 4 trial evaluating rituximab for treatment of IgA nephropathy is underway, with status not specified.
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: Study of Telitacicept in Patients With Refractory IgA Nephropathy [Phase 2, Phase 3]
Phase 2/Phase 3 clinical trial update for telitacicept in refractory IgA nephropathy; status not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation [Phase 2]
Phase 2 trial update on safety and efficacy of LNP023 in IgA nephropathy has been completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy [Phase 2]
Phase 2 trial of AVB-S6-500 in IgA nephropathy was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX [Phase 2]
Phase 2 trial evaluating bardoxolone methyl in rare chronic kidney diseases has completed, with results posted January 18, 2022. Diseases st…